

Press release from Emotra AB (publ)

Göteborg, June 7, 2017

The subscription period for EMOTRA AB's rights issue for the market launch of EDOR[®] begins today

Today, June 7, 2017, is the first day in the subscription period for the new rights issue in EMOTRA AB ("Emotra"). This new share issue is also open to the general public. The subscription period ends on June 21, 2017. If fully subscribed, this new rights issue will provide Emotra with a cash injection of appr. 17.5 MSEK before issue expenses. The Company has already received subscription commitments for approximately 3 MSEK, or about 17 percent of the issue amount. Memorandum, teaser and subscription forms are available on the web sites of Emotra (www.emotra.se), Sedermera Fondkommission (www.sedermera.se) and AktieTorget (www.aktietorget.se).

Comments from Claes Holmberg, Emotra's CEO

"Emotra has closed EUDOR-A, a large, clinical multi-centre study which over several years has involved more than 1,500 patients at 16 leading psychiatric clinics in nine European countries, to examine the method's efficacy, reliability and how it can best be utilised in clinical practice. In March, 2017, EUDOR-A was closed, on budget and on schedule, and with very satisfying results—a tenfold reduction in the suicide rate in the patient group that was tested using EDOR[®] and in which the test results were used as a basis for decisions to initiate suicide-preventive measures. We now see strong opportunities to commercialise EDOR[®], especially since a number of clinical studies, most recently EUDOR-A, have provided clinical proof that hyporeactive individuals are extra vulnerable to suicide attempts and because the method is an objective and reliable way to determine whether a person is hyporeactive. In March, 2017, a special consensus meeting was held in Rome where the participants – leading European suicide researchers and psychiatric clinics – evaluated EUDOR-A. After in-depth discussions and interpretations of the results, the meeting participants decided in favour of launching the method in Europe. In our opinion, EDOR[®] is thus a mature product that has proven itself amply in clinical practice and, therefore, the time is ripe for a commercial launch of the method. In order to reap the full market potential and commercial opportunities of the EDOR[®] method, we plan on raising approximately 17.5 MSEK through a new rights issue. This new capital will allow us to carry out our market launch of the method. We plan on initiating our EDOR[®] marketing activities as soon as in Q2/Q3 of 2017, with the goal of achieving a broad market acceptance among leading psychiatric clinics in the western hemisphere within two years."

Rights issue in anticipation of the commercial introduction of EDOR[®]

Emotra is now issuing new shares to raise a total of appr. 17.5 MSEK. Emotra's primary goal with the capital that this new rights issue will provide is to finance the Company's planned market launch of EDOR[®] following the promising results of our clinical multi-centre study, EUDOR-A. The funds will primarily be used to establish a marketing organisation within the Company with the goal of making EDOR[®] commercially available. Emotra also intends to dedicate some of the funds to continued product development of both our hardware and our software, as well as to continued research in order to secure the Company's position at the forefront of this area.

The offering in summary

- **Subscription period:** June 7 to 21, 2017.
- **Subscription price:** SEK 3.30 per share
- **Record day:** June 2, 2017. The final day for trading in the company's shares including the right to obtain subscription rights was May 31, 2017, and the first day without subscription rights was June 1, 2017.
- **Preferential right:** Shareholders whose Emotra shares were registered on June 2, 2017 will have preferential right to subscribe for shares in the new share issue. Each outstanding share entitles the owner to one (1) subscription right. Nine (9) subscription rights allow the shareholder to subscribe to five (5) new shares. Please note that this new share issue is also open to the general public.
- **Issue volume:** The offering comprises a maximum of 5,287,700 new shares. If fully subscribed, this new share issue will provide the Company with a cash injection of 17,449,410 SEK before issue expenses.
- **Number of shares outstanding before the new issue:** 9,517,860.
- **Dilution if fully subscribed:** Approximately 35.7 percent.

- **Value (pre-money):** Approximately 31.4 MSEK.
- **Trading in subscription rights:** Trading in subscription rights will be carried out on AktieTorget from June 7 to June 19, 2017.
- **Trading in PSS:** Trading in PSS (Paid Subscribed Shares) will be carried out on AktieTorget from June 7, 2017, until the new share issue has been registered at Bolagsverket (The Swedish Companies Registration Office). We expect this registration to be completed in the middle of July 2017.
- **Subscription commitments:** Emotra has received subscription commitments for a total of 3 MSEK, which equals approximately 17% of the total issue value.
- **Market place:** Emotra's share is listed on AktieTorget.
- **ISIN code:** SE0006851507

Investor meetings

In connection with our new rights issue, representatives of Emotra will take part in investor meetings to present the company's operations and future plans. Attending these sessions are free of charge, and we will be serving a light snack. For further information about our meetings, please visit Sedermera Fondkommission's web site (www.sedermera.se) or contact Sedermera Fondkommission by telephone, +46 40 615 14 10, or by e-mail addressed to event@sedermera.se.

Date and time	Organiser	Address and town	Registration
June 9, 2017 11:30 am – 1 pm	Sedermera Fondkommission	Elite Plaza Hotel Västra Hamngatan 3, Göteborg	http://www.sedermera.se/evenemang
June 14, 2017 11:30 am – 1 pm	Sedermera Fondkommission	Scandic Klara Slöjdgatan 7, Stockholm	http://www.sedermera.se/evenemang
June 15, 2017 5:30 pm – 7 pm	Sedermera Fondkommission	Sedermera Fondkommission Norra Vallgatan 64, Malmö	http://www.sedermera.se/evenemang

Memorandum (including complete terms and instructions and further information about subscription commitments) as well as a teaser and subscription form without preferential right are available on the Company's web site (www.emotra.se), Sedermera Fondkommission's web site (www.sedermera.se) and AktieTorget's web site (www.aktietorget.se).

Financial Advisor

Emotra's Financial Advisor in connection with this new rights issue is Sedermera Fondkommission.

For further information about the rights issue, please contact:

Sedermera Fondkommission
Telephone: +46 40 615 14 10
E-mail: info@sedermera.se

For further information about Emotra, please contact:

Claes Holmberg, CEO
Telephone: +46 708 25 45 47
E-mail: claes@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR®, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.